Evolus, Inc. Logo

Evolus, Inc.

EOLS

(1.5)
Stock Price

12,66 USD

-32% ROA

9254.43% ROE

-19.45x PER

Market Cap.

1.041.059.250,00 USD

631.45% DER

0% Yield

-22.49% NPM

Evolus, Inc. Stock Analysis

Evolus, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Evolus, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-76.68x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (-1391%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 ROE

The stock's ROE indicates a negative return (-556.51%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-66%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-24), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Evolus, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Evolus, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Evolus, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Evolus, Inc. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 34.925.000 100%
2020 56.540.000 38.23%
2021 99.673.000 43.27%
2022 148.616.000 32.93%
2023 197.292.000 24.67%
2023 202.085.000 2.37%
2024 267.636.000 24.49%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Evolus, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2015 20.681.000
2016 12.607.000 -64.04%
2017 6.689.000 -88.47%
2018 6.487.000 -3.11%
2019 3.973.000 -63.28%
2020 1.722.000 -130.72%
2021 2.064.000 16.57%
2022 4.742.000 56.47%
2023 6.348.000 25.3%
2023 6.556.000 3.17%
2024 9.400.000 30.26%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Evolus, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 9.883.000
2016 7.033.000 -40.52%
2017 4.819.000 -45.94%
2018 29.146.000 83.47%
2019 0 0%
2020 0 0%
2021 0 0%
2022 130.198.000 100%
2023 0 0%
2023 157.454.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Evolus, Inc. EBITDA
Year EBITDA Growth
2015 -30.564.000
2016 -19.640.000 -55.62%
2017 -11.508.000 -70.66%
2018 -45.930.000 74.94%
2019 -92.976.000 50.6%
2020 -59.029.000 -57.51%
2021 -64.282.000 8.17%
2022 -59.498.000 -8.04%
2023 -77.496.000 23.22%
2023 -30.240.000 -156.27%
2024 -18.680.000 -61.88%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Evolus, Inc. Gross Profit
Year Gross Profit Growth
2015 -416.000
2016 -326.000 -27.61%
2017 -218.000 -49.54%
2018 -9.000 -2322.22%
2019 26.911.000 100.03%
2020 38.241.000 29.63%
2021 56.139.000 31.88%
2022 92.729.000 39.46%
2023 135.568.000 31.6%
2023 135.393.001 -0.13%
2024 185.620.000 27.06%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Evolus, Inc. Net Profit
Year Net Profit Growth
2015 -31.112.000
2016 -20.065.000 -55.06%
2017 -4.480.000 -347.88%
2018 -46.867.000 90.44%
2019 -90.034.000 47.95%
2020 -163.013.000 44.77%
2021 -46.810.000 -248.24%
2022 -74.412.000 37.09%
2023 -67.692.000 -9.93%
2023 -61.685.000 -9.74%
2024 -45.400.000 -35.87%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Evolus, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -2
2016 -1 0%
2017 0 0%
2018 -2 100%
2019 -3 66.67%
2020 -5 25%
2021 -1 0%
2022 -1 100%
2023 -1 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Evolus, Inc. Free Cashflow
Year Free Cashflow Growth
2015 -36.384.000
2016 -13.267.000 -174.24%
2017 -13.035.000 -1.78%
2018 -25.676.000 49.23%
2019 -97.950.000 73.79%
2020 -61.009.000 -60.55%
2021 -34.358.000 -77.57%
2022 -11.713.000 -193.33%
2023 -34.821.000 66.36%
2023 -35.635.000 2.28%
2024 -7.724.000 -361.35%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Evolus, Inc. Operating Cashflow
Year Operating Cashflow Growth
2015 -36.384.000
2016 -13.267.000 -174.24%
2017 -13.035.000 -1.78%
2018 -25.667.000 49.21%
2019 -93.383.000 72.51%
2020 -57.871.000 -61.36%
2021 -33.388.000 -73.33%
2022 -8.774.000 -280.53%
2023 -34.821.000 74.8%
2023 -34.008.000 -2.39%
2024 -6.470.000 -425.63%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Evolus, Inc. Capital Expenditure
Year Capital Expenditure Growth
2015 0
2016 0 0%
2017 0 0%
2018 9.000 100%
2019 4.567.000 99.8%
2020 3.138.000 -45.54%
2021 970.000 -223.51%
2022 2.939.000 67%
2023 0 0%
2023 1.627.000 100%
2024 1.254.000 -29.74%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Evolus, Inc. Equity
Year Equity Growth
2015 12.002.000
2016 -7.106.000 268.9%
2017 -75.543.000 90.59%
2018 -123.025.000 38.6%
2019 -213.059.000 42.26%
2020 -376.072.000 43.35%
2021 -422.882.000 11.07%
2022 18.499.000 2385.97%
2023 -19.368.000 195.51%
2023 -20.689.000 6.39%
2024 19.314.000 207.12%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Evolus, Inc. Assets
Year Assets Growth
2015 81.301.000
2016 77.495.000 -4.91%
2017 152.233.000 49.09%
2018 171.844.000 11.41%
2019 240.442.000 28.53%
2020 209.068.000 -15.01%
2021 257.483.000 18.8%
2022 177.983.000 -44.67%
2023 167.971.000 -5.96%
2023 188.998.000 11.13%
2024 233.772.000 19.15%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Evolus, Inc. Liabilities
Year Liabilities Growth
2015 69.299.000
2016 84.601.000 18.09%
2017 227.776.000 62.86%
2018 87.460.000 -160.43%
2019 160.985.000 45.67%
2020 282.026.000 42.92%
2021 175.607.000 -60.6%
2022 159.484.000 -10.11%
2023 187.339.000 14.87%
2023 209.687.000 10.66%
2024 214.458.000 2.22%

Evolus, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.77
Net Income per Share
-0.85
Price to Earning Ratio
-19.45x
Price To Sales Ratio
4.4x
POCF Ratio
-20.26
PFCF Ratio
-19.26
Price to Book Ratio
53.59
EV to Sales
4.54
EV Over EBITDA
-32.16
EV to Operating CashFlow
-21.02
EV to FreeCashFlow
-19.88
Earnings Yield
-0.05
FreeCashFlow Yield
-0.05
Market Cap
1,04 Bil.
Enterprise Value
1,07 Bil.
Graham Number
2.42
Graham NetNet
-1.3

Income Statement Metrics

Net Income per Share
-0.85
Income Quality
1.41
ROE
92.54
Return On Assets
-0.23
Return On Capital Employed
-0.18
Net Income per EBT
1
EBT Per Ebit
1.66
Ebit per Revenue
-0.14
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.15
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0.08
Gross Profit Margin
0.68
Operating Profit Margin
-0.14
Pretax Profit Margin
-0.22
Net Profit Margin
-0.22

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.81
Free CashFlow per Share
-0.86
Capex to Operating CashFlow
-0.06
Capex to Revenue
0.01
Capex to Depreciation
0.65
Return on Invested Capital
-0.23
Return on Tangible Assets
-0.32
Days Sales Outstanding
66.58
Days Payables Outstanding
49.34
Days of Inventory on Hand
64.22
Receivables Turnover
5.48
Payables Turnover
7.4
Inventory Turnover
5.68
Capex per Share
0.05

Balance Sheet

Cash per Share
1,49
Book Value per Share
0,31
Tangible Book Value per Share
-0.77
Shareholders Equity per Share
0.31
Interest Debt per Share
2.1
Debt to Equity
6.31
Debt to Assets
0.52
Net Debt to EBITDA
-0.99
Current Ratio
2.92
Tangible Asset Value
-0,05 Bil.
Net Current Asset Value
-0,06 Bil.
Invested Capital
179245000
Working Capital
0,10 Bil.
Intangibles to Total Assets
0.29
Average Receivables
0,04 Bil.
Average Payables
0,01 Bil.
Average Inventory
12464000
Debt to Market Cap
0.12

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Evolus, Inc. Dividends
Year Dividends Growth

Evolus, Inc. Profile

About Evolus, Inc.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

CEO
Mr. David Moatazedi
Employee
304
Address
520 Newport Center Drive
Newport Beach, 92660

Evolus, Inc. Executives & BODs

Evolus, Inc. Executives & BODs
# Name Age
1 Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.
Chief Medical Officer and Head of Research & Development
70
2 Mr. Nareg Sagherian
Head of Global Investor Relations & Corporate Communications
70
3 Mr. David Moatazedi
President, Chief Executive Officer & Director
70
4 Ms. Tomoko Yamagishi-Dressler
Chief Marketing Officer
70
5 Mr. Jeffrey J. Plumer
General Counsel
70
6 Ms. Jessica Novak
Senior Vice President of Human Resources
70
7 Ms. Sandra Beaver
Chief Financial Officer
70
8 Mr. Kurt Knab
Vice President of Sales
70

Evolus, Inc. Competitors